Jan. 25, 2007 — Abiomed, Inc. has announced the development of a pediatric circulatory support technology. Currently in pre-clinical studies, Abiomed has developed a catheter-based heart pump, similar to the Impella LP2.5, that provides left-ventricular support to small pediatric patients requiring preconditioning prior to a cardiac intervention, or to recover patients who are either post-surgery, cannot be weaned from bypass, or who have endocarditis.
Designed to operate as either a pulsatile device providing up to 120 beats per minute or as a continuous flow technology, the technology is estimated to provide circulatory support for approximately two weeks.
The company plans to pursue CE Mark and FDA Humanitarian Device Exemption approval for the technology
For more details visit: www.abiomed.com.
June 19, 2024 
